The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

Can be refractory to corticosteroids (PMID 30837232)

Publications

Li R, Lee G, El-Sherief A

Immunotherapy causing pneumonitis in a patient with non-small cell lung cancer (NSCLC).

BMJ case reports. 2019;12(3)

Shannon VR

Pneumotoxicity associated with immune checkpoint inhibitor therapies.

Current opinion in pulmonary medicine. 2017;23(4):305-316

Tabchi S, Messier C, Blais N

Immune-mediated respiratory adverse events of checkpoint inhibitors.

Current opinion in oncology. 2016;28(4):269-77